Penn Medicine, IBX, and Regent Surgical Launch Tri-Party Company to Build 18+ Philadelphia ASCs
What is the new Penn Medicine, Independence Blue Cross, and Regent Surgical partnership? The three organizations have formed a new jointly owned company to develop at least 18 ambulatory surgery centers across Greater Philadelphia, announced September 24, 2026. Penn Medicine contributes its physician network and clinical brand, Independence Blue Cross (IBX) brings payer-side access and affordability expertise, and Regent Surgical brings decades of ASC development and operations experience. The first site is expected to open in 2027, with the venture aimed at expanding lower-cost, high-quality outpatient surgical capacity across the region.
This is a rare three-way structure — health system, payer, and ASC operator co-owning a single de novo development company — rather than the more common health-system-led or PE-backed ASC platform. For growth and operations leaders, it’s a template worth watching: aligning payer incentives directly with site-of-care shift to outpatient settings could accelerate ASC buildout in markets where health systems and payers have historically negotiated at arm’s length instead of co-investing.
Use it for: A model of a payer, a health system and an ASC operator co-owning de novo surgery centers. The Philadelphia Inquirer reports plans for at least 18 centers across the five-county region, with Regent Surgical managing them, Penn clinicians providing care and the first site expected in 2027.
Watch out for: Ownership percentages, the company name and the investment amount were not disclosed. IBX’s “as much as a 50% discount” is a general claim about ASCs versus hospital outpatient departments, not a result for these centers, and the 33% local versus 56% national ASC migration figures are Regent-supplied data from a Kythera Labs claims analysis.
Try this: If you run surgical or GI sites in a similar market, list which of your procedures are ASC-eligible and which payers could steer them, then compare this structure with others in five major ASC-related deals and investment moves in 2026.
While we aim to share useful and relevant resources, we do not guarantee the accuracy of content on this site or any external links. Views and opinions expressed in referenced content do not necessarily reflect those of Healthcare Growth Strategies.
Who is involved in the new Philadelphia ASC venture?
Penn Medicine, Independence Blue Cross (IBX), and Regent Surgical announced on September 24, 2026 that they are launching a new, jointly owned company to develop ambulatory surgery centers across Greater Philadelphia. Penn Medicine supplies clinical expertise and its physician network, IBX brings payer-side experience in access and affordability, and Regent Surgical contributes ASC development and operations know-how.
How many ASCs does the partnership plan to build, and when?
The venture plans to support the creation of at least 18 ambulatory surgery centers, accelerating what the partners describe as one of the region’s largest outpatient surgery networks. The first local facility is expected to open in 2027.
Why does a payer-provider-ASC operator joint venture matter for healthcare growth leaders?
It’s a distinctive de novo structure: instead of a health system or PE-backed platform building ASCs alone, a payer is co-investing directly alongside the provider and the ASC operator. That alignment of payer incentives with outpatient site-of-care shift is a model other multi-site operators and payers may look to replicate as surgical volume continues moving out of hospitals.